ALNYLAM PHARMACEUTICALS, INC. Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount of $5.60 million as of 2012-09-30, per its 10-Q filed 2012-11-05.
Discontinued › Notes
us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount · last filed 2012-11-05
- 2012-09-30: Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $5.60M.
- 2012-06-30: Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $5.60M.
| Period end | Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount |
|---|---|
| 2012-09-30 | $5.60M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $5.60M 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |